A phase I, single-blind study to determine the safety, tolerability and pharmacodynamic profiles of a reference antigen combined with a new vaccine adjuvant (IMP321) versus the reference antigen alone and the reference vaccine in healthy young male volunteers

Next Previous
Trial Profile

A phase I, single-blind study to determine the safety, tolerability and pharmacodynamic profiles of a reference antigen combined with a new vaccine adjuvant (IMP321) versus the reference antigen alone and the reference vaccine in healthy young male volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2006

At a glance

  • Drugs Hepatitis B vaccine; Hepatitis B vaccine; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Immutep

    • Most Recent Events

    • 30 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top